Zoe Bayliss Wong

Nov 5, 2024 | nature.com | Niveditha Ravindra |Zoe Bayliss Wong |Zoë C Wong |Jeffery J. Auletta |Yi-Bin Chen |Steven M. Devine | +4 more

AbstractMeasurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. Persistence of mutated NPM1 or FLT3-ITD in the blood of adult patients with AML in first complete remission (CR1) prior to allogeneic hematopoietic cell transplant (alloHCT) associates with increased relapse and death after transplant.

Oct 24, 2024 | nature.com | Niveditha Ravindra |Zoe Bayliss Wong |Zoë C Wong |Jeffery J. Auletta |Yi-Bin Chen |Steven M. Devine | +4 more

AbstractRoutine genetic profiling of acute myeloid leukemia (AML) at initial diagnosis has allowed subgroup specific prognostication, drug development, and clinical management strategies. The optimal approach for treatment response assessment for AML subgroups has not yet however been determined.